Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Explore mechanism data, evidence tiers, safety, and regulatory context for every compound in the Fnx catalog. Each peptide has its own research profile, filter by category or follow a tag from any product page.
FDA approved with randomized controlled trials behind the approved use.
A large or maturing human RCT base, but not (yet) FDA approved for this use.
Registered and used abroad (e.g. Russia) on modest, mostly single institution trials.
A plausible mechanism, but human efficacy for the marketed use is unproven.
Animal/in vitro data and anecdote only, little to no human evidence and real safety unknowns.
A 15 amino acid peptide fragment based on a sequence in human gastric juice, studied extensively for tissue repair and angiogenic signaling in preclinical models.
The synthetic actin binding fragment (LKKTETQ) of thymosin beta-4, studied for cell migration, angiogenesis, and systemic tissue repair in animal models.
A naturally occurring copper binding tripeptide first isolated from human plasma, investigated for collagen synthesis, tissue remodeling, and broad gene expression modulation.
The C terminal tripeptide of α MSH, studied for anti inflammatory activity via NF-κB modulation, without the melanocortin or tanning effects of the parent hormone.
A co formulated three peptide research blend of GHK-Cu, BPC-157, and TB-500, positioned for multi pathway tissue repair and skin quality research.